

Oral presentation

Open Access

Prognostic importance of left ventricular hypertrophy in patients undergoing dobutamine stress testing

Charaslak Charoenpanichkit*, Timothy M Morgan, Craig A Hamilton, Eric L Wallace, Killian Robinson, William O Ntim and W Gregory Hundley

Address: Wake Forest University, Winston-Salem, NC, USA

* Corresponding author

from 13th Annual SCMR Scientific Sessions
Phoenix, AZ, USA. 21-24 January 2010

Published: 21 January 2010

Journal of Cardiovascular Magnetic Resonance 2010, **12**(Suppl 1):O7 doi:10.1186/1532-429X-12-S1-O7

This abstract is available from: <http://jcmr-online.com/content/12/S1/O7>

© 2010 Charoenpanichkit et al; licensee BioMed Central Ltd.

Objective

To determine if left ventricular hypertrophy (LVH) influences the prognostic utility of dobutamine cardiovascular magnetic resonance (DCMR) stress test results.

Background

Although LVH is associated with adverse cardiovascular outcomes and occurs in 10% to 25% of patients referred for clinical DCMR stress testing, the influence of LVH on the prognostic utility of DCMR wall motion stress test results is unknown.

Methods

Three hundred sixty-two (362) participants, aged 64 ± 12 years (55% men) underwent DCMR for determination of inducible ischemia, and then were followed for 6 ± 2 (range 0.5 to 11.5) years to assess the post-DCMR occurrence of MI or cardiac death assessed by researchers blinded to the results of DCMR. Using previously established criteria, LVH was defined as $> 96 \text{ g/m}^2$ in men and $> 77 \text{ g/m}^2$ in women.

Results

LVH was present in 56 participants (16% of the men and 15% of the women, referred for testing; $p = 0.77$). Abnormal LV geometry was identified in 40% of the participants with 24% concentric remodeling, 6% concentric hypertrophy, and 10% eccentric hypertrophy. Seventy-one (20%) participants experienced a MI or cardiac death. The MI and cardiac death rate was more frequent in those

with versus those without LVH (32% vs. 17%, $p = 0.01$). In a multivariable analysis that accounted for the presence of pre-existing coronary artery disease, hypertension, diabetes, stress-induced ischemia, or reduced resting LVEF, LVH was the independent predictor of MI and cardiac death (HR 1.8, 95% CI 1.05-3.22, $p = 0.032$) Figure 1.

Conclusion

LVH forecasts future MI and cardiac death in patients with chest pain referred for dobutamine cardiac stress testing. LVH should be measured and reported in non-invasive cardiac stress tests, particularly those without inducible ischemia, in which otherwise one would assume a favorable cardiac prognosis.




Figure 1

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

